Company news: Forest Labs

Share this article:
FDA approved Forest's Daliresp (roflumilast) for the treatment of severe chronic COPD in adults 18 and up. The daily pill is indicated for decreasing the frequency of flare-ups or worsening of symptoms including breathlessness, chronic cough and excessive phlegm associated with bronchitis. The first-in-class drug is not indicated for treatment of primary emphysema, another form of COPD.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.